Key result
Elevated CXCL9 and CXCL10 chemokines improve incident stroke risk prediction beyond traditional vascular scoring.
Why the study?
Do serum immune biomarker signatures (CXCL9 and CXCL10) predict incident stroke beyond the Global Vascular Risk Score (GVRS)?
Do serum immune biomarker signatures (CXCL9 and CXCL10) predict incident stroke beyond the Global Vascular Risk Score (GVRS)?
The study aims to evaluate whether CXCL9 and CXCL10 predict incident stroke beyond established risk scores.
To derive stroke-predicting serum immune biomarker signatures that predict incident stroke and assess their prognostic value beyond the Global Vascular Risk Score (GVRS).
No takes yet. Share an insight, caveat, or question.
Shahrestani et al. (2026) studied this question. IFN-γ-inducible chemokines CXCL9 and CXCL10 were evaluated for their prognostic value in predicting incident stroke beyond the Global Vascular Risk Score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: